Risk Factors and Preventive Measures for Lung Cancer in the European Union
Open Access
- 27 August 2024
- journal article
- research article
- Published by MDPI AG in Epidemiologia
- Vol. 5 (3) , 539-546
Abstract
Background: Lung cancer is worldwide one of the most common types of cancer with still very high mortality rates. The aim of this study was to identify and demonstrate correlations between lung cancer mortality rates and potential influencing factors in EU countries. Methods: This retrospective study investigated the connections between the mortality rates in the EU countries (n = 28) and potential influencing factors. The significant factors from the correlation analysis were identified using a stepwise multiple regression analysis. Results: The most important factors for both genders are the incidence of lung cancer, the price of tobacco, and the number of doctors per 100,000 inhabitants. Conclusion: Lung cancer is a significant global health challenge. The study identified potential strategies for reducing the mortality rate from lung cancer. These strategies include an increase in the number of physicians, enhanced accessibility to cutting-edge antineoplastic medications, and state-funded coverage of the associated costs. It would be beneficial for politicians to consider implementing LDCT screening for the early detection of the disease. The implementation of uniform healthcare system optimization across the EU, combined with improvements in socio-economic conditions, has the potential to mitigate the risk of developing lung cancer.Keywords
Funding Information
- Heidelberg University
This publication has 26 references indexed in Scilit:
- Proteogenomics of Non-smoking Lung Cancer in East Asia Delineates Molecular Signatures of Pathogenesis and ProgressionCell, 2020
- Lung cancer mortality reduction by LDCT screening—Results from the randomized German LUSI trialInternational Journal of Cancer, 2019
- Association of Primary Care Physician Supply With Population Mortality in the United States, 2005-2015JAMA Internal Medicine, 2019
- Long‐term safety and survival with gefitinib in select patients with advanced non–small cell lung cancer: Results from the US IRESSA Clinical Access Program (ICAP)Cancer, 2018
- Economic downturns, universal health coverage, and cancer mortality in high-income and middle-income countries, 1990–2010: a longitudinal analysisThe Lancet, 2016
- HPV and lung cancer risk: A meta-analysisJournal of Clinical Virology, 2015
- Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5·24 million UK adultsThe Lancet, 2014
- Prävention, Diagnostik, Therapie und Nachsorge des LungenkarzinomsPneumologie, 2010
- Incidence of human papilloma virus in lung cancerLung Cancer, 2009
- LungenkarzinomDie Innere Medizin, 2006